$185 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$61.99 - $107.24The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$1.47 (1.41%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$185 Billion|
|Dividend Yield||$1.47 (1.41%)|
|1 Year Return||+51.7%|
|Outstanding Shares||1.77 Billion|
|Avg 30 Day Volume||862 Thousand|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
CEO: Lars Fruergaard Joergensen
Industry: Medicinal and Botanical Manufacturing
SEB Equities upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a hold rating to a buy rating in a research report report published on Monday, The Fly reports. A number of other equities research ...Dakota Financial News, 3 days ago
Lets take a quick look at the insulin market. Even with the advent of biosimilars Lilly, Novo Nordisk and Sanofi still dominate the market. While insulin remains the most heavily rebated drug it at...Diabetic Investor, 4 days ago
BAGHDAD--(BUSINESS WIRE)-- #BPTW4Iraq--Novo Nordisk Iraq, an affiliate of the global healthcare company with more than 90 years of innovation and leadership in diabetes care, has been officially re...Business Wire, 5 days ago